期刊
IMMUNOTHERAPY
卷 9, 期 11, 页码 913-927出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2017-0052
关键词
chemotherapy; immunomodulation; immunotherapy; microenvironment; non-small cell lung cancer
类别
资金
- National Institutes of Health [P30 CA008748]
- U.S. Department of Defense [BC132124, LC160212]
- Mesothelioma Applied Research Foundation
- Baker Street Foundation
- Joanne and John DallePezze Foundation
- Derfner Foundation
- Commonwealth Foundation for Cancer Research
- Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center
Spurred by the survival benefits seen with the use of checkpoint blockade in non-small-cell lung cancer (NSCLC), there has been a growing interest in the potential applications of immunotherapy. Despite this, the objective response rate for single-agent immunotherapy remains <= 20% in patients with advanced NSCLC. A combinatorial approach that utilizes both chemotherapy and immunotherapy is a potential strategy to increase antitumor efficacy. Accumulating evidence has shown that the immunomodulatory effects of chemotherapeutic agents can be exploited in a combinational approach. Herein, we review the influence of specific chemotherapeutic agents on the tumor immune microenvironment in preclinical and clinical studies, and establish the rationale for combination chemoimmunotherapy for the treatment of NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据